You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm will scale US-based testing capacity for its LiquidHallmark liquid biopsy assay, which uses amplicon-based technology to detect cancer-related mutations.
Ceres plans to develop its Nanotrap technology to isolate undetectable levels of circulating tumor DNA in blood samples from non-small cell lung cancer patients.
The company believes its tests can already help oncologists better assess post-surgery risk, though prospective validation would be necessary for broad claims.
The company's HCCscreen assay will be used in a liver cancer screening public health initiative, generating real-world data on the test's clinical validity and impact.
The test uses a targeted methylation sequencing panel to detect more than 50 cancer types across all stages and pinpoint a cancer's tissue of origin.
The European Commission awarded a consortium of private companies and academic researchers €759,000 recently to carry out their plans.
The company presented new evidence for the sensitivity of its multi-cancer early detection test and robustness of its automated library prep system.
The firm also discussed recent studies comparing its UltraSeek lung cancer assay with more established liquid biopsy tests to detect drug-resistant mutations.
The company reported total revenues of RMB123.9 million ($18.2 million) for the quarter, driven largely by growth in its central laboratory business.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The company will use a portion of the proceeds to enter into capped call transactions and the remainder for various corporate activities.
The group is developing an ultrasensitive nanoparticle-enhanced plasmonic biosensor to detect RAS single nucleotide variants in plasma.
The company also announced John Leite, the former leader of clinical business development activities at Illumina, had joined the firm as chief business officer.
Novitas added multiple leukemia biomarkers to its coverage determination, as well as the ThyGeNEXT molecular panel.
The company highlighted efforts to expand the use of its tests in the analysis of cerebrospinal fluid, an area in which research collaborations have begun to yield some data.
Despite the dramatic growth in overall testing revenue, the company's core oncology testing revenue dropped significantly quarter-over-quarter.
A negative preliminary decision regarding reimbursement for the company's flagship colon cancer screening test in the US remains an issue for the company.
The Chinese company is branching out from its core genomics business to liquid biopsy cancer screening and monitoring as it eyes areas for global expansion.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.
The Chinese company reported revenues of RMB112.0 million ($16.5 million), driven by growth in sales of both its LDT services and IVD products.
Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner.
Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.
A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.
In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.